Treatments that include inhibitors of both PI3K/AKT and MAPK/ERK signaling pathways59 and/or treatments that target the miRNAs that regulate the downstream targets involved in these well-known signaling pathways hold considerable promise for treating various cancers. This evidence concerns the gene MAPK1 and cancer.